TY - JOUR
T1 - Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention
T2 - A Cross-Sectional Study
AU - Giantini, Astuti
AU - Timan, Ina Susianti
AU - Listiyaningsih, Erlin
AU - Dharma, Rahajuningsih
AU - Setiabudy, Rianto
AU - Alwi, Idrus
AU - Partakusuma, Lia Gardenia
AU - Indrasari, Nuri Dyah
AU - Harahap·, Alida Roswita
AU - Suparmin·, Siskawati
AU - Sahar, Windy
AU - Sukmawan, Renan
N1 - Funding Information:
The research conducted by authors private fund, there was no research grant or sponsor to be disclosed.
Publisher Copyright:
© 2021. All Rights Reserved.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in patients undergoing percutaneous coronary intervention and determine factors affecting clopidogrel resistance. METHODS: The subjects were 119 patients who underwent percutaneous coronary intervention (PCI) and had given loading dose of 600 mg clopidogrel. Blood samples were taken at 6 hour after clopidogrel loading dose. Platelet aggregation was measured by LTA and Verify Now. RESULTS: LTA and VerifyNow assay showed fair agreement with Kappa=0.270, p=0.001. The proportion of resistance to clopidogrel using VerifyNow was 21.8% and LTA was 47.1%. Patients with diabetes melitus were more likely to develop clopidogrel resistance than patients without diabetes (OR of 7.67; 95% CI: 1.87-31.50; p=0.005). CONCLUSION: The ability of LTA and VerifyNow in detecting clopidogrel resistance were not comparable. Multivariate analysis results for VerifyNow shows diabetes mellitus as the greatest predictors of clopidogrel resistance.
AB - BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in patients undergoing percutaneous coronary intervention and determine factors affecting clopidogrel resistance. METHODS: The subjects were 119 patients who underwent percutaneous coronary intervention (PCI) and had given loading dose of 600 mg clopidogrel. Blood samples were taken at 6 hour after clopidogrel loading dose. Platelet aggregation was measured by LTA and Verify Now. RESULTS: LTA and VerifyNow assay showed fair agreement with Kappa=0.270, p=0.001. The proportion of resistance to clopidogrel using VerifyNow was 21.8% and LTA was 47.1%. Patients with diabetes melitus were more likely to develop clopidogrel resistance than patients without diabetes (OR of 7.67; 95% CI: 1.87-31.50; p=0.005). CONCLUSION: The ability of LTA and VerifyNow in detecting clopidogrel resistance were not comparable. Multivariate analysis results for VerifyNow shows diabetes mellitus as the greatest predictors of clopidogrel resistance.
KW - agreement
KW - clopidogrel resistance
KW - LTA
KW - predictor
KW - VerifyNow
UR - http://www.scopus.com/inward/record.url?scp=85108601516&partnerID=8YFLogxK
U2 - 10.18585/inabj.v13i2.1477
DO - 10.18585/inabj.v13i2.1477
M3 - Article
AN - SCOPUS:85108601516
SN - 2085-3297
VL - 13
SP - 163
EP - 169
JO - Indonesian Biomedical Journal
JF - Indonesian Biomedical Journal
IS - 2
ER -
